Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Nat Chem. 2020 Feb 6;12(4):331–337. doi: 10.1038/s41557-020-0420-9

Proteomimetics as protein-inspired scaffolds with defined tertiary folding patterns

W Seth Horne 1,*, Tom N Grossmann 2,*
PMCID: PMC7739441  NIHMSID: NIHMS1651875  PMID: 32029906

Abstract

Proteins have evolved as a variable platform that provides access to molecules with diverse shapes, sizes, and functions. These features have inspired chemists for decades to seek artificial mimetics of proteins with improved or novel properties. Such work has focused primarily on small protein fragments, often isolated secondary structures; however, there has lately been a growing interest in the design of artificial molecules that mimic larger, more complex tertiary folds. In this Perspective, we define these agents as “proteomimetics” and discuss the recent advances in the field. Proteomimetics can be divided into three categories: (1) protein domains with side chain functionality that alters the native linear chain topology, (2) protein domains in which the chemical composition of the polypeptide backbone has been partially altered, and (3) protein-like folded architectures that are composed entirely of non-natural monomer units. We give an overview of these proteomimetic approaches and outline remaining challenges facing the field.

Keywords: Bioconjugation, Foldamers, Protein engineering, Protein mimetics, Tertiary structure


Proteins are defined by a hierarchy of structural complexity which is founded on their primary amino acid sequence. Local and long-range intramolecular interactions among backbone and side-chain atoms determine higher order folding behavior by facilitating the formation of secondary structures and their arrangement into tertiary structure (Fig. 1a).1 Protein folds have evolved to manifest varied and unique functional characteristics that are central to biological systems. The mimicry of protein structure and function represents a long-standing challenge to chemists and has been approached with artificial agents of varying size and complexity (Fig. 1b). At one end of this hierarchy are molecules intended to recreate features of a few amino acids or isolated secondary structure—generally referred to as peptidomimetics.2,3 Early examples of peptidomimetics include mimics of primary structures found in small peptide hormones and peptide substrates of protease enzymes.2 The latter were developed as inhibitors of protease function, and clinical use of these compounds revolutionized the treatment of diseases such as HIV and hepatitis C.4 Later, the stabilization or recreation of secondary structure in the absence of a protein context became a central focus of endeavors toward peptidomimetics. The challenges inherent to the mimicry of these more complex folded structures led to invention of a number of distinct approaches, including peptides containing artificial building blocks, macrocyclic agents, and entirely artificial backbones with defined folding propensities (Fig. 1b).3,5,6 Over the last decade, peptidomimetics have become valuable bioactive agents and drug candidates of particular utility in targeting the extended and flat biomacromolecular surfaces involved in protein-protein interactions.7

Figure 1 |. Overview of protein structures and their mimetics.

Figure 1 |

a, Hierarchy of peptide and protein structure, which spans in complexity from primary sequence (light blue) to folded secondary structure (blue) and tertiary structure (tan). b, Corresponding hierarchy of peptide and protein mimetics. Peptidomimetics encompass agents that recreate primary sequence or isolated secondary structure and can be broadly classified into small molecules, peptides containing chemical modification (e.g., macrocyclization shown), or artificial backbones with defined folds (“foldamers”). Proteomimetics, the focus of this Perspective, comprise agents that recreate protein tertiary structure and can be classified into molecules with altered chain topology, partially artificial backbone compositions, or completely artificial backbone compositions. Example peptidomimetic and proteomimetic structures are shown with non-natural parts highlighted in red. (Coordinates for structures from PDB entries 1A46, 1IJA, 1T3R, 1UBQ, 2AGH, 2QMT, 2YJ1, 2YXJ, 3OXC, 4N5T, 5KVN; CSD entry 697088; and references67,85.)

Building on the above precedent on peptidomimetics, there has been a recent growing interest in the design of artificial agents that mimic larger and more complex tertiary folds. While a daunting challenge, efforts along these lines have been enabled by advances in methodology for protein chemical synthesis8 and bioconjugation9 as well as the emergence of powerful protein engineering approaches including directed evolution,10 computational design,11 and non-canonical amino acid mutagenesis.12 A critical mass of results now suggests a burgeoning field of proteomimetics which are conceptually linked to, yet distinct from, their smaller peptidomimetic counterparts. The term proteomimetic has found limited prior use in the literature, primarily to describe molecules that recreate isolated segments of protein secondary structure.5,13,14 Herein, we propose a definition of proteomimetics as molecules that have a defined tertiary fold and recreate certain features of a protein such as shape, recognition properties or enzymatic activity. In this perspective, we highlight recent advances towards proteomimetic structures based on a classification of these agents into one of three categories (Fig. 1b). Most examples of proteomimetics reported to date were obtained by chemical protein engineering, an approach that can provide protein-like molecules with altered chain topology and/or partially artificial backbone composition introduced in a chain composed mainly of natural amino acids. Other work has addressed the challenge of proteomimetic design by applying non-natural building blocks to construct completely artificial backbones able to adopt large, complex folds.

Altered chain topology

In natural proteins, the linear topology of the main chain is often altered by disulfide bridges formed between two cysteines spatially aligned in the folded state but distant in primary sequence. Such intramolecular crosslinks are frequently located between distinct secondary structures thereby stabilizing the domain tertiary fold. While the installation of non-native disulfide bridges has been widely applied for the stabilization of tertiary structures, the short distance of the resulting crosslink (Cβ-Cβ-distance ≤ 5.5 Å)15 considerably restricts the number of possible modification sites. Seeking to overcome this limitation, work dating back to the 1960s has shown the use of biselectrophilic reagents to crosslink the amines of two lysine side chains, giving access to structurally diverse bridges.1618 This approach was used to probe the spatial proximity of lysine residues16 and to investigate the effect of intramolecular crosslinks on protein folding and tertiary structure stability.19 Given the high abundance of surface lysine residues in proteins and the resulting selectivity issues, these macrocyclization reactions were limited to a few protein model systems such as ribonuclease A.16,17,19

Aiming for more general strategies to modify protein chain topology, disulfide mimetics have been obtained by crosslinking two reduced cysteine side chains with biselectrophilic agents. Examples include the installation of tetrafluorobenzene (1, Fig. 2a) for the crosslinking of H2 relaxin20 and the application of oxetane-based scaffold 2 for the modification of antibody fragments and a diphtheria toxin-derived carrier protein.21 These biselectrophilic agents connect the two cysteine sulfur atoms via a three- or four-carbon bridge. Depending of the location of the original disulfide, the introduction of the organic linker can result in altered protein function.20 Cysteine-based protein crosslinking approaches have also been developed to introduce novel intradomain crosslinks. For example, a chloroacetamide-modified lysine has been incorporated into chemically synthesized affibodies and albumin-binding domains to capture an appropriately aligned cysteine side chain providing thioether linkage 3.22,23 Broadening the application of this strategy to larger proteins, non-canonical mutagenesis was used to introduce a tyrosine-derived electrophilic amino acid into a myoglobin-based cyclopropanation biocatalyst.24 The resulting thioether crosslink 4, stabilized the enzyme towards thermal stress and high concentrations of organic cosolvent enabling the cyclopropanation of water-insoluble substrates.24 To avoid complications in heterologous expression of proteins that result from the use of non-natural amino acids, two or three solvent exposed cysteines have been introduced and reacted with bis- or triselectrophilic agents resulting in the in situ cyclization of proteins (INCYPRO). The most pronounced stabilization effects from the INCYPRO strategy were obtained with a triselectrophilic crosslink (5) that resulted in bicyclic versions of the transcriptional coactivator domain KIX (Fig. 2b) and of the enzyme Sortase A.25 The stabilized Sortase A variant was able to catalyze reactions under denaturing conditions. Notably, although INCYPRO requires the absence of additional solvent-accessible cysteines, the chemistry tolerates the presence of an active site cysteine in Sortase A.25

Figure 2 |. Examples of proteomimetics based on altered chain topology.

Figure 2 |

a, Overview of bridging moieties including linker structures resulting from reactions of biselectrophilic crosslinkers or non-natural amino acids with cysteine (1, 2, 3, 4, 7, 8), symmetric trivalent bridges used to crosslink three cysteine residues (5, 9) and a linker resulting from a ring-closing metathesis between two modified asparagine residues (6). b, Model of the INCYPRO stabilized KIX domain based on an NMR structure of the unmodified protein (PDB 2AGH).25 c, NMR structure of a chemically dimerized parallel coiled-coil.32 d, NMR structure (PDB 5V2G) of the de novo designed tricyclic three-helix CovCore structure.37 Proteins are depicted in cartoon representation with hydrophobic core residues shown as sticks (grey). Crosslinks are highlighted (red) and shown as sticks.

The selective chemical modification of entire protein domains as described above is limited by the inherent selectivity issues when addressing natural amino acids. This renders the total chemical synthesis an appealing alternative strategy in particular when aiming for smaller peptide-derived proteomimetics. Chemical synthesis allows the introduction of a broad range of non-natural building blocks and topologies, and the application of methodologies originally developed in the context of classic peptidomimetics. In construction of such synthetic proteomimetics, secondary structures such as β-hairpins and α-helices have been utilized as assembly units to obtain higher-order folding patterns. A β-hairpin comprises two antiparallel β-strands connected by a short loop structure. Because hairpins typically exhibit a low folding propensity in isolation, modifications are required to stabilize the fold. Most approaches to this end involve macrocyclization either via side chain-to-side chain bridges or by head-to-tail connections using turn-inducing loop structures.3,26 Recently, a β-sheet motif within a WW domain was stabilized using long polyethyleneglycol-based crosslinkers (6).27 A noteworthy aspect of that work was the finding that relatively long and flexible crosslink architectures can efficiently stabilize a complex tertiary structure.

In addition to stabilizing natural tertiary structures, chemical crosslinks have been applied to link isolated secondary structures in nonlinear topologies and facilitate their artificial spatial arrangement into complex protein-like architectures. Early examples involve the use of cyclic β-hairpins28 or porphyrins29 as scaffolds for the covalent attachment of four helical peptides resulting in folded higher-order structures. In later work, natural and de novo designed coiled coils30,31 served as starting point for the design of crosslinked helix bundles.3234 Dimeric coiled coils (Fig. 2c) have been stabilized using various linkages such as ethylene glycol (7) and dibenzyl ether-based structures (8) installed via biselectrophilc crosslinkers and targeting two cysteine side chains.32,33 Analogously, crosslinked trimeric helix bundles were created revealing that robust assembly relies on carefully designed crosslinkers and supporting interhelical hydrophobic contacts.32,34 Hydrophobic bis- and triselectrophiles, previously used for the generation of mono- and bicylic peptides,35,36 have also been utilized to create covalent linkages in the hydrophobic core of designed artificial tertiary folds (termed the CovCore approach).37 These proteomimetics were de novo designed using computational approaches and resulted in structures of high thermal stability, as observed for a triangular, head-to-tail cyclized three-helix domain arranged around a central 1,3,5-trimethyl benzene linker (9).37

The crosslinking approaches described above implement changes in protein topology via the covalent modification of amino acids side chains resulting in permanent structural constraints. Alternatively, secondary structure elements, in particular α-helices, have been assembled using controllable moieties to devise dynamic proteomimetics. A switchable scaffold has been constructed via head-to-head ligation of a parallel coiled-coil connected by a peptide loop containing a binding epitope.38 Receptor binding to this epitope leads to opening of the coiled-coil structure, which can be detected in real-time employing an appropriately aligned fluorophore/quencher pair. In addition, three-helix assemblies have been templated using nucleic acid triplex formation facilitating the dynamic self-assembly of protein-like structures39 and highlighting the potential of orthogonal self-assembly systems in the design of proteomimetics.

Partially artificial backbones

The canonical l-α-peptide backbone connectivity in proteins is not unique in conveying the ability to adopt a protein-like folding pattern.4042 Alteration of backbone composition was initially conceived in the context of peptidomimetics, where diverse artificial backbones—termed “foldamers”43—have been used to mimic helices and other isolated segments of protein secondary structure.3,5 Though primarily applied to generate peptidomimetics, alteration of backbone chemical composition also has utility in recreating larger, more complex folds and thus proteomimetics. Changing the backbone of a protein can have dramatic effects, such as altered folding behavior, molecular recognition, stability to degradation, and dynamics. Building blocks that have been applied to protein backbone modification are diverse in structure (Fig. 3a). Some are close structural analogues of native l-α-residues, while others bear little resemblance to a natural protein backbone. In addition to structural diversity, there is considerable variation in the number and density of backbone modifications that have been applied in a given chain. Substitution can involve a single amino acid, a contiguous segment of the backbone, or the replacement of amino acids interspersed throughout a domain.

Figure 3 |. Examples of proteomimetics based on partially artificial backbone compositions.

Figure 3 |

a, Chemical structures of selected residue types used to construct modified protein backbones. b-g Experimentally determined folded structures of modified-backbone proteomimetics. Native l-α-residues are shown in grey and non-natural monomers in red. Each panel is labeled with the domain mimicked and a list of residue types in the chain. b, NMR structure of a zinc finger domain mimic with an artificial helix (PDB 5N14).58 c, Crystal structure of a trimeric assembly formed by a sequence derived from Aβ with turn-inducing and sheet-disrupting modifications (PDB 4NTR).94 d, NMR structure of a knottin mimic with a heterochiral backbone comprising a d-α-peptide core and native loop.67 e, NMR structure of a zinc finger domain mimic with backbone modifications in the helix and hairpin regions (PDB 5US3).71 f, Crystal structure of a helix-turn-helix scaffold modified in the helices (PDB 4WPB).72 g NMR structure of a de novo disulfide-rich scaffold harboring modifications throughout the helix, loop, turn, and sheet (PDB 6E5J).74

Pioneering efforts at protein backbone alteration in tertiary folds involved single-atom substitution to modulate forces that drive folding and assembly (e.g., replacement of a natural α-residue [10] with an N-Me-α analogue [11]).4449 Later work broadened this approach—often referred to as “protein prosthesis”—to encompass more extensive changes to backbone chemical composition at a single site, with a particular eye to controlling conformational preferences at β-turns.5054 The concept of isolated prosthetic modification has been leveraged more recently as a strategy to control dynamics in the study of an intrinsically disordered sequence through the replacement of one or two α-residues with rigidified Cα-methyl analogues (12) in the activation domain from the p160 transcriptional co-activator for thyroid hormone and retinoid receptors.55 Collectively, the above precedents establish that backbone connectivity of a natural sequence can be changed without abolishing the ability to adopt a complex tertiary fold. An important characteristic shared in these examples is that the altered backbone connectivity was isolated to one or two sites. Although such limited modification can have profound effects, chemists have been motivated to produce complex tertiary folds from backbones more artificial in composition. To this end, a number of reports have demonstrated mimicry of prototype proteins by variants in which an α-helical segment is replaced by a helix mimic. In some cases, the prosthetic helix replacement was entirely artificial in chemical composition. For example, substitution of a helix in the chemokine interleukin 8 with a helix comprised of β3-residues (13)56 and substitution of a helix in the transcription factor Hif1α with an aromatic oligoamide helix mimetic57 both led to functional variants of the prototype protein. Related, the α-helix in a zinc finger domain was recently replaced by a helical oligomer of urea-based residues (14).58 Beyond adopting a native-like fold and metal-binding site (Fig. 3b), the chimeric zinc finger domain was able to bind double-stranded DNA. This interaction is driven largely by contacts with the α-helix replaced in the prototype, underscoring the effective structural mimicry of this portion of the protein by the prosthetic segment.

An alternate approach to prosthetic protein backbone modification is to intersperse artificial units alongside natural α-residues to replace a local segment of secondary structure in a folded protein with a backbone that displays the natural side-chain sequence on a partially artificial main chain. An attractive characteristic of this approach is that it does not require a priori knowledge of a secondary structure mimetic compatible with a given prototype. Instead, careful modification enables the biological side-chain sequence to recapitulate key non-covalent contacts that drive folding and function on the newly artificial backbone. Early efforts towards the incorporation of locally heterogeneous backbones in protein tertiary folds involved replacement of a single secondary structure element. Examples of α-helix modifications include transposition of side chains from Cα to N in the enzyme ribonuclease A through incorporation of peptoid residues (15)59 and the introduction of extra backbone methylene units in an engineered chorismite mutase through α- to β3-residue substitution.60 Localized backbone alterations in β-sheet-rich folds including β3-residues, N-Me-α-residues, and ornithine connected via its δ-amine (δ-Orn, 16) have been applied to generate bioactive analogues of an antiangiogenic protein fragment61 and to control the assembly behavior of amyloidogenic sequences (Fig. 3c).6265 The latter efforts were motivated by a desire to obtain fundamental insights into as well as potential inhibitors of amyloid formation related to diseases such as Alzheimer’s and Huntington’s. Protein domains in which the functionally relevant segment is a surface-exposed loop can also be subject to prosthetic modification, as illustrated by the introduction of a flexible spacer in an ion channel inhibitory conotoxin66 and the grafting of an engineered receptor-binding peptide loop onto a disulfide-rich d-α-residue (17) based knottin scaffold (Fig. 3d).67 In both cases, the modification improved stability to degradation by proteolytic enzymes.

The above examples illustrate that backbone alterations can be accommodated in any of the common secondary structures, but can such changes be applied globally? Answering this question requires consideration of two key challenges. The first relates to monomer selection. Because different backbones are predisposed to stabilize different local folds, it is difficult to create a proteomimetic consisting of an array of different secondary structures based on just a single α-residue replacement type. The second challenge relates to the plasticity of natural side-chain sequences with respect to functioning on backbones of altered composition. In many of the examples cited above, backbone modifications made to an isolated part of a protein had a small unfavorable effect on fold stability and/or function. This is not surprising, as the sequences being mimicked did not evolve to function on the types of employed backbones. Despite these challenges, significant progress has been made in generating proteomimetics from more densely modified backbones.

One of the first examples to apply systematic backbone modification throughout a tertiary structure entailed the mimicry of a small, phage-derived peptide inhibitor of vascular endothelial growth factor signaling with an ordered but irregular folding pattern.68 Substitution of selected α-residues in the native sequence with a combination of β3-residues and cyclic β-residue 18 led to an analogue that showed an improvement in stability to degradation by protease enzymes, albeit at the expense of a modest loss in receptor affinity. Moving toward mimicry of more complex folds required the application of a wider assortment of α-residue replacements. An early illustration of this is seen in the development of heterogeneous-backbone variants of the B1 domain of Streptococcal protein G (GB1), which contains helix, sheet, turn, and loop secondary structures and is stabilized by a well-packed hydrophobic core.69 The key to successful recreation of the GB1 tertiary fold was to employ a variety of different backbone modification types (e.g., d-α-, N-Me-α-, Cα-Me-α-, and β3-residues, as well as cyclic β-residue 19 and cyclic γ-residue 20). Subsequent work on the GB1 system yielded a set of general design principles for the application of diverse building block types in the construction of heterogeneous-backbone proteomimetics.70 These design principles have since been shown applicable to a variety of other proteins.

Aiming for the reproduction of a zinc finger, it was found that some heterogeneous-backbone variants of the prototype containing a combination of β3- and N-Me-α-residues exhibited higher thermodynamic folded stability than the natural backbone (Fig. 3e).71 This was a noteworthy result in illustrating that a biologically derived side-chain sequence can fold more favorably on a heterogeneous backbone. This study also highlights challenges in developing proteomimetics based on heterogeneous backbones, as a metal-binding β-turn in the prototype proved completely intolerant to a number of backbone alterations known to effectively stabilize turns in other contexts. The ability to mimic isolated helical secondary structures with heterogeneous backbones has been leveraged to produce mimics of a bioactive helix-turn-helix tertiary scaffold in which the helices incorporate a combination of Cα-Me-α-, β3-, and cyclic β-residues (Fig. 3f).72 Noteworthy here was the observation that receptor affinities of the variants were in some cases indistinguishable from the natural-backbone prototype. The functional potential of heterogeneous-backbone proteomimetics was further highlighted by a recent report of artificial variants of the protein ubiquitin which are able to engage in native multi-protein signaling pathways.73 De novo designed tertiary structures have also served as inspiration for the design of proteomimetics, as shown by the backbone modification of a computationally designed disulfide-rich scaffold to yield mimetics with identical folds and increased proteolytic stability (Fig. 3g).74

Completely artificial backbones

The design of proteomimetics based on completely artificial backbones is a particularly challenging endeavor as it requires the de novo design of a side-chain sequence able to specify a tertiary fold, and at the same time a backbone capable of manifesting the sequence-encoded fold. Notably, the resulting architectures, unhindered by natural constraints of protein-like folding patterns, offer the prospect of functions beyond those known from natural systems. Pioneering efforts that paved the way toward completely artificial proteomimetics involved a range of oligamide-based foldamers capable of adopting robust secondary structures.4042,75 While these molecules were inspired to some degree by biomacromolecules, many of the resulting folds depart considerably from nature complicating their use for the creation of tertiary folding patterns. The difficulties associated with the design of completely artificial proteomimetics explain the smaller number of mimetics compared to the two categories discussed above. Already existing examples, however, highlight the potential of complex architectures that lack analogous prototypes in nature.

Early efforts towards complex folded structures composed entirely of artificial monomer units entailed the design of amphiphilic helices that assemble into defined helix bundles. Examples with folded structures characterized at high resolution include an oligomer of β3-residues (13) that forms an octameric bundle (Fig. 4a)76 and an oligomer of urea-based monomers (14) that forms a hexameric assembly (Fig. 4b).77 Both these systems are formally an example of quaternary structure since each consists of an assembly of isolated secondary structure elements. Nevertheless, these prototypes were later advanced to create analogous helix-bundle assemblies with complex functions, including small molecule recognition,78 catalysis,79,80 and metal binding.81 The first examples toward unimolecular tertiary structure from completely artificial backbones involved the creation of helix-turn-helix motifs by a design analogous to that of above mentioned helix bundles.82 Results here were encouraging, although the proposed tertiary structures were not confirmed by X-ray crystallography or NMR.

Figure 4 |. Examples of proteomimetics based on entirely artificial backbone compositions.

Figure 4 |

a-b, Crystal structures of an octameric helix bundle assembly formed by a β3-peptide (a)76 and a hexameric helix bundle assembly formed by an urea oligomer (b);77 structures are colored by chain. c, Chemical structures of monomers used in the construction of aromatic oligoamide foldamers. d, Crystal structure of fructose (yellow) in complex with an aromatic oligoamide helical capsule.83 e, Crystal structure of an aromatic oligoamide helix-turn-helix motif.84

Oligoamides based on rigid aromatic building blocks (e.g., 21–29, Fig. 4c) have proven a particularly robust platform for creating complex folding patterns. A sophisticated example of a corresponding unimolecular folding motif is the helical molecular capsule that lacks an analogous architecture in natural proteins. Patterning aromatic amide building blocks of differing length, geometry, and composition along a helical chain yielded a defined internal pocket that could selectively bind a monosaccharide guest (Fig. 4d).83 Notably, this architecture is formally at the level of secondary structure; however, it is able to accomplish a function (molecular encapsulation) that in a protein would require a higher order tertiary fold. Design principles toward aromatic oligoamides have been advanced more recently to construct true tertiary folds comprise multiple secondary structures arrayed in a single entirely artificial chain. Corresponding helix-turn-helix (Fig. 4e)84 and helix-sheet-helix motifs,85 as well as multistranded sheets86 have been designed and characterized at atomic resolution. Most noteworthy, the helix-turn-helix system displays cooperativity in its folding behavior87—a hallmark feature of natural proteins.

Conclusions and future directions

The unique folding properties and functions of proteins have stimulated diverse efforts to understand these phenomena at the molecular level, and to mimic or improve certain protein features. Initially, small protein fragments were the focus of such work resulting in a multitude of approaches toward peptidomimetic agents. Recently there has been an increasing interest in the mimicry of larger more complex folds resulting in tertiary structure mimetics, which we term proteomimetics herein. These efforts have been mainly motivated by basic questions regarding protein folding and recognition processes as well as the design of high affinity ligands or artificial agents with enzymatic activity. The past has seen the emergence of novel mimicry approaches that have often been applied individually, but more recent results show a trend towards the use of different approaches in combination. Notably, while proteomimetic approaches in the past have predominantly focused on the characterization of folding properties of the resulting molecules, current efforts appear to focus more on their use as biomimetic agents, highly selective binders or catalysts. In addition, recent advances in allied fields will enable the more efficient development and construction of proteomimetics. For example, one can expect that the number of biocompatible reactions used for the construction of proteomimetics will continuously increase, and that computational de novo protein design will give access to entirely novel proteomimetics scaffolds. Regarding efforts toward development of proteomimetics as bio-inspired catalysts, the rapidly evolving field of artificial metalloenzymes88,89 will provide a rich source of inspiration. Notably, covalently modified proteins have already been evolved by using metal-coordinating non-natural amino acids,9092 or artificial post-translational modification.93 Proteomimetic approaches may be diverse, but scientists working in this area are united by a shared curiosity about protein function and the search for artificial substitutes. The emerging field of proteomimetics research promises to benefit from this diversity and lead to important advances that address central questions associated with human health and a more sustainable society.

Acknowledgements

We thank Paramjit Arora and Bradley Pentelute for providing coordinates of proteomimetic structures from their published work. T.N.G. is grateful for support by the European Research Council (ERC starting grant, no. 678623). W.S.H. thanks the National Institutes of Health (GM1071610) for financial support.

Footnotes

Competing financial interests

T.N.G. is listed as an inventor on a patent application related to the INCYPRO stabilization approach.

References

  • 1.Sali A, Shakhnovich E & Karplus M How does a protein fold? Nature 369, 248–251 (1994). [DOI] [PubMed] [Google Scholar]
  • 2.Gante J Peptidomimetics - Tailored enzyme inhibitors. Angew. Chem. Int. Ed 33, 1699–1720 (1994). [Google Scholar]
  • 3.Pelay-Gimeno M, Glas A, Koch O & Grossmann TN Structure-based design of inhibitors of protein-protein interactions: Mimicking peptide binding epitopes. Angew. Chem. Int. Ed 54, 8896–8927 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Clercq ED The design of drugs for HIV and HCV. Nat. Rev. Drug. Discov 6, 1001 (2007). [DOI] [PubMed] [Google Scholar]
  • 5.Azzarito V, Long K, Murphy NS & Wilson AJ Inhibition of α-helix-mediated protein-protein interactions using designed molecules. Nat. Chem 5, 161–173 (2013). [DOI] [PubMed] [Google Scholar]
  • 6.Robertson NS & Spring DR Using peptidomimetics and constrained peptides as valuable tools for inhibiting protein-protein interactions. Molecules 23 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Scott DE, Bayly AR, Abell C & Skidmore J Small molecules, big targets: Drug discovery faces the protein–protein interaction challenge. Nat. Rev. Drug. Discov 15, 533 (2016). [DOI] [PubMed] [Google Scholar]
  • 8.Kent SBH Novel protein science enabled by total chemical synthesis. Protein Sci. 28, 313–328 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Krall N, da Cruz FP, Boutureira O & Bernardes GJL Site-selective protein-modification chemistry for basic biology and drug development. Nat. Chem 8, 102–112 (2016). [DOI] [PubMed] [Google Scholar]
  • 10.Renata H, Wang ZJ & Arnold FH Expanding the enzyme universe: Accessing non-natural reactions by mechanism-guided directed evolution. Angew. Chem. Int. Ed 54, 3351–3367 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Huang PS, Boyken SE & Baker D The coming of age of de novo protein design. Nature 537, 320–327 (2016). [DOI] [PubMed] [Google Scholar]
  • 12.Chin JW Expanding and reprogramming the genetic code. Nature 550, 53–60 (2017). [DOI] [PubMed] [Google Scholar]
  • 13.Orner BP, Ernst JT & Hamilton AD Toward proteomimetics: Terphenyl derivatives as structural and functional mimics of extended regions of an α-helix. J. Am. Chem. Soc 123, 5382–5383 (2001). [DOI] [PubMed] [Google Scholar]
  • 14.Rennie YK, McIntyre PJ, Akindele T, Bayliss R & Jamieson AG A TPX2 proteomimetic has enhanced affinity for Aurora-A due to hydrocarbon stapling of a helix. ACS Chem. Biol 11, 3383–3390 (2016). [DOI] [PubMed] [Google Scholar]
  • 15.Dombkowski AA, Sultana KZ & Craig DB Protein disulfide engineering. FEBS Lett. 588, 206–212 (2014). [DOI] [PubMed] [Google Scholar]
  • 16.Marfey PS, Nowak H, Uziel M & Yphantis DA Reaction of bovine pancreatic ribonuclease A with 1,5-difluoro-2,4-dinitrobenzene. J. Biol. Chem 240, 3264-& (1965). [PubMed] [Google Scholar]
  • 17.Hartman FC & Wold F Bifunctional reagents. Cross-linking of pancreatic ribonuclease with a diimido ester. J. Am. Chem. Soc 88, 3890-& (1966). [Google Scholar]
  • 18.Uy R & Wold F in Protein Crosslinking: Biochemical and Molecular Aspects (ed Mendel Friedman) 169–186 (Springer; US, 1977). [Google Scholar]
  • 19.Lin SH, Konishi Y, Denton ME & Scheraga HA Influence of an extrinsic cross-link on the folding pathway of ribonuclease A. Conformational and thermodynamic analysis of cross-linked (lysine7-lysine41)-ribonuclease A. Biochemistry 23, 5504–5512 (1984). [DOI] [PubMed] [Google Scholar]
  • 20.Luhmann T, Mong SK, Simon MD, Meinel L & Pentelute BL A perfluoroaromatic abiotic analog of H2 relaxin enabled by rapid flow-based peptide synthesis. Org. Biomol. Chem 14, 3345–3349 (2016). [DOI] [PubMed] [Google Scholar]
  • 21.Martinez-Saez N et al. Oxetane grafts installed site-selectively on native disulfides to enhance protein stability and activity in vivo. Angew. Chem. Int. Ed 56, 14963–14967 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Ekblad T et al. Synthesis and chemoselective intramolecular crosslinking of a HER2-binding affibody. Biopolymers 92, 116–123 (2009). [DOI] [PubMed] [Google Scholar]
  • 23.Lindgren J & Karlstrom AE Intramolecular thioether crosslinking of therapeutic proteins to increase proteolytic stability. ChemBioChem 15, 2132–2138 (2014). [DOI] [PubMed] [Google Scholar]
  • 24.Moore EJ, Zorine D, Hansen WA, Khare SD & Fasan R Enzyme stabilization via computationally guided protein stapling. Proc. Natl. Acad. Sci. USA 114, 12472–12477 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Pelay-Gimeno M, Bange T, Hennig S & Grossmann TN In situ cyclization of native proteins: Structure-based design of a bicyclic enzyme. Angew. Chem. Int. Ed 57, 11164–11170 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Robinson JA β-hairpin peptidomimetics: Design, structures and biological activities. Acc. Chem. Res 41, 1278–1288 (2008). [DOI] [PubMed] [Google Scholar]
  • 27.Xiao Q et al. Stapling of two PEGylated side chains increases the conformational stability of the WW domain via an entropic effect. Org. Biomol. Chem 16, 8933–8939 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Mutter M et al. Template-assembled synthetic proteins with 4-helix-bundle topology. Total chemical synthesis and conformational studies. J. Am. Chem. Soc 114, 1463–1470 (1992). [Google Scholar]
  • 29.Sasaki T & Kaiser ET Synthesis and structural stability of helichrome as an artificial hemeproteins. Biopolymers 29, 79–88 (1990). [DOI] [PubMed] [Google Scholar]
  • 30.Lupas AN & Bassler J Coiled coils - A model system for the 21st century. Trends Biochem. Sci 42, 130–140 (2017). [DOI] [PubMed] [Google Scholar]
  • 31.Beesley JL & Woolfson DN The de novo design of α-helical peptides for supramolecular self-assembly. Curr. Opin. Biotechnol 58, 175–182 (2019). [DOI] [PubMed] [Google Scholar]
  • 32.Wuo MG, Hong SH, Singh A & Arora PS Synthetic control of tertiary helical structures in short peptides. J. Am. Chem. Soc 140, 16284–16290 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Wuo MG, Mahon AB & Arora PS An effective strategy for stabilizing minimal coiled coil mimetics. J. Am. Chem. Soc 137, 11618–11621 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Wang C et al. Site-specific isopeptide bridge tethering of chimeric gp41 N-terminal heptad repeat helical trimers for the treatment of HIV-1 infection. Sci. Rep 6 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Timmerman P, Beld J, Puijk WC & Meloen RH Rapid and quantitative cyclization of multiple peptide loops onto synthetic scaffolds for structural mimicry of protein surfaces. ChemBioChem 6, 821–824 (2005). [DOI] [PubMed] [Google Scholar]
  • 36.Heinis C & Winter G Encoded libraries of chemically modified peptides. Curr. Opin. Chem. Biol 26, 89–98 (2015). [DOI] [PubMed] [Google Scholar]
  • 37.Dang BB et al. De novo design of covalently constrained mesosize protein scaffolds with unique tertiary structures. Proc. Natl. Acad. Sci. USA 114, 10852–10857 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Mueller C & Grossmann TN Coiled-coil peptide beacon: A tunable conformational switch for protein detection. Angew. Chem. Int. Ed 57, 17079–17083 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Lou CG et al. Peptide-oligonucleotide conjugates as nanoscale building blocks for assembly of an artificial three-helix protein mimic. Nat. Commun 7 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Hill DJ, Mio MJ, Prince RB, Hughes TS & Moore JS A field guide to foldamers. Chem. Rev 101, 3893–4012 (2001). [DOI] [PubMed] [Google Scholar]
  • 41.Bautista AD, Craig CJ, Harker EA & Schepartz A Sophistication of foldamer form and function in vitro and in vivo. Curr. Opin. Chem. Biol 11, 685–692 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Goodman CM, Choi S, Shandler S & DeGrado WF Foldamers as versatile frameworks for the design and evolution of function. Nat. Chem. Biol 3, 252 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Gellman SH Foldamers: A manifesto. Acc. Chem. Res 31, 173–180 (1998). [Google Scholar]
  • 44.Rajarathnam K et al. Neutrophil activation by monomeric interleukin-8. Science 264, 90–92 (1994). [DOI] [PubMed] [Google Scholar]
  • 45.Chapman E, Thorson JS & Schultz PG Mutational analysis of backbone hydrogen bonds in staphylococcal nuclease. J. Am. Chem. Soc 119, 7151–7152 (1997). [Google Scholar]
  • 46.Lu W, Qasim MA, Laskowski M & Kent SBH Probing intermolecular main chain hydrogen bonding in serine proteinase-protein inhibitor complexes: Chemical synthesis of backbone-engineered turkey ovomucoid third domain. Biochemistry 36, 673–679 (1997). [DOI] [PubMed] [Google Scholar]
  • 47.Beligere GS & Dawson PE Design, synthesis, and characterization of 4-ester CI2, a model for backbone hydrogen bonding in protein α-helices. J. Am. Chem. Soc 122, 12079–12082 (2000). [Google Scholar]
  • 48.Wales TE & Fitzgerald MC The energetic contribution of backbone-backbone hydrogen bonds to the thermodynamic stability of a hyperstable P22 Arc repressor mutant. J. Am. Chem. Soc 123, 7709–7710 (2001). [DOI] [PubMed] [Google Scholar]
  • 49.Deechongkit S et al. Context-dependent contributions of backbone hydrogen bonding to β-sheet folding energetics. Nature 430, 101–105 (2004). [DOI] [PubMed] [Google Scholar]
  • 50.Baca M, Kent SBH & Alewood PF Structural engineering of the HIV-1 protease molecule with a β-turn mimic of fixed geometry. Protein Sci. 2, 1085–1091 (1993). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Jean F et al. Synthesis and structural and functional evaluation of a protein modified with a β-turn mimic. J. Am. Chem. Soc 120, 6076–6083 (1998). [Google Scholar]
  • 52.Viles JH et al. Design, synthesis and structure of a zinc finger with an artificial β-turn. J. Mol. Biol 279, 973–986 (1998). [DOI] [PubMed] [Google Scholar]
  • 53.Kaul R, Angeles AR, Jäger M, Powers ET & Kelly JW Incorporating β-turns and a turn mimetic out of context in loop 1 of the WW domain affords cooperatively folded β-sheets. J. Am. Chem. Soc 123, 5206–5212 (2001). [DOI] [PubMed] [Google Scholar]
  • 54.Arnold U et al. Protein prosthesis: A semisynthetic enzyme with a β-peptide reverse turn. J. Am. Chem. Soc 124, 8522–8523 (2002). [DOI] [PubMed] [Google Scholar]
  • 55.Schmidtgall B et al. Dissecting mechanism of coupled folding and binding of an intrinsically disordered protein by chemical synthesis of conformationally constrained analogues. Chem. Commun 53, 7369–7372 (2017). [DOI] [PubMed] [Google Scholar]
  • 56.David R et al. Artificial chemokines: Combining chemistry and molecular biology for the elucidation of interleukin-8 functionality. J. Am. Chem. Soc 130, 15311–15317 (2008). [DOI] [PubMed] [Google Scholar]
  • 57.Burslem GM et al. Towards “bionic” proteins: Replacement of continuous sequences from HIF-1α with proteomimetics to create functional p300 binding HIF-1α mimics. Chem. Commun 52, 5421–5424 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Lombardo CM et al. Design and structure determination of a composite zinc finger containing a nonpeptide foldamer helical domain. J. Am. Chem. Soc 141, 2516–2525 (2019). [DOI] [PubMed] [Google Scholar]
  • 59.Lee B-C & Zuckermann RN Protein side-chain translocation mutagenesis via incorporation of peptoid residues. ACS Chem. Biol 6, 1367–1374 (2011). [DOI] [PubMed] [Google Scholar]
  • 60.Mayer C, Müller MM, Gellman SH & Hilvert D Building proficient enzymes with foldamer prostheses. Angew. Chem. Int. Ed 53, 6978–6981 (2014). [DOI] [PubMed] [Google Scholar]
  • 61.Hegedüs Z et al. Foldameric α/β-peptide analogs of the β-sheet-forming antiangiogenic anginex: Structure and bioactivity. J. Am. Chem. Soc 135, 16578–16584 (2013). [DOI] [PubMed] [Google Scholar]
  • 62.Cheng P-N, Liu C, Zhao M, Eisenberg D & Nowick JS Amyloid β-sheet mimics that antagonize protein aggregation and reduce amyloid toxicity. Nat. Chem 4, 927 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Kar K et al. β-Hairpin-mediated nucleation of polyglutamine amyloid formation. J. Mol. Biol 425, 1183–1197 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Kar K et al. Backbone engineering within a latent β-hairpin structure to design inhibitors of polyglutamine amyloid formation. J. Mol. Biol 429, 308–323 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Kreutzer AG & Nowick JS Elucidating the structures of amyloid oligomers with macrocyclic β-hairpin peptides: Insights into alzheimer’s disease and other amyloid diseases. Acc. Chem. Res 51, 706–718 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Green BR et al. Conotoxins containing nonnatural backbone spacers: Cladistic-based design, chemical synthesis, and improved analgesic activity. Chem. Biol 14, 399–407 (2007). [DOI] [PubMed] [Google Scholar]
  • 67.Mong SK et al. Heterochiral knottin protein: Folding and solution structure. Biochemistry 56, 5720–5725 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Haase HS et al. Extending foldamer design beyond α-helix mimicry: α/β-peptide inhibitors of vascular endothelial growth factor signaling. J. Am. Chem. Soc 134, 7652–7655 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Reinert ZE, Lengyel GA & Horne WS Protein-like tertiary folding behavior from heterogeneous backbones. J. Am. Chem. Soc 135, 12528–12531 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.George KL & Horne WS Foldamer tertiary structure through sequence-guided protein backbone alteration. Acc. Chem. Res 51, 1220–1228 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.George KL & Horne WS Heterogeneous-backbone foldamer mimics of zinc finger tertiary structure. J. Am. Chem. Soc 139, 7931–7938 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Checco JW et al. Targeting diverse protein–protein interaction interfaces with α/β-peptides derived from the Z-domain scaffold. Proc. Natl. Acad. Sci. USA 112, 4552–4557 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Werner HM, Estabrooks SK, Preston GM, Brodsky JL & Horne WS Exploring the functional consequences of protein backbone alteration in ubiquitin through native chemical ligation. ChemBioChem 20, 7752–7755 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Cabalteja CC, Mihalko DS & Horne WS Heterogeneous-backbone foldamer mimics of a computationally designed, disulfide-rich miniprotein. ChemBioChem 20, 103–110 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Guichard G & Huc I Synthetic foldamers. Chem. Commun 47, 5933–5941 (2011). [DOI] [PubMed] [Google Scholar]
  • 76.Daniels DS, Petersson EJ, Qiu JX & Schepartz A High-resolution structure of a β-peptide bundle. J. Am. Chem. Soc 129, 1532–1533 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Collie GW et al. Shaping quaternary assemblies of water-soluble non-peptide helical foldamers by sequence manipulation. Nat. Chem 7, 871 (2015). [DOI] [PubMed] [Google Scholar]
  • 78.Miller JP, Melicher MS & Schepartz A Positive allostery in metal ion binding by a cooperatively folded β-peptide bundle. J. Am. Chem. Soc 136, 14726–14729 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Wang PSP, Nguyen JB & Schepartz A Design and high-resolution structure of a β3-peptide bundle catalyst. J. Am. Chem. Soc 136, 6810–6813 (2014). [DOI] [PubMed] [Google Scholar]
  • 80.Bécart D et al. Helical oligourea foldamers as powerful hydrogen bonding catalysts for enantioselective C–C bond-forming reactions. J. Am. Chem. Soc 139, 12524–12532 (2017). [DOI] [PubMed] [Google Scholar]
  • 81.Collie GW et al. Molecular recognition within the cavity of a foldamer helix bundle: Encapsulation of primary alcohols in aqueous conditions. J. Am. Chem. Soc 139, 6128–6137 (2017). [DOI] [PubMed] [Google Scholar]
  • 82.Lee B-C, Zuckermann RN & Dill KA Folding a nonbiological polymer into a compact multihelical structure. J. Am. Chem. Soc 127, 10999–11009 (2005). [DOI] [PubMed] [Google Scholar]
  • 83.Chandramouli N et al. Iterative design of a helically folded aromatic oligoamide sequence for the selective encapsulation of fructose. Nat. Chem 7, 334 (2015). [DOI] [PubMed] [Google Scholar]
  • 84.De S et al. Designing cooperatively folded abiotic uni- and multimolecular helix bundles. Nat. Chem 10, 51–57 (2018). [DOI] [PubMed] [Google Scholar]
  • 85.Lamouroux A et al. Controlling dipole orientation through curvature: Aromatic foldamer bent β-sheets and helix–sheet–helix architectures. J. Am. Chem. Soc 139, 14668–14675 (2017). [DOI] [PubMed] [Google Scholar]
  • 86.Atcher J et al. Aromatic β-sheet foldamers based on tertiary squaramides. Chem. Commun 55, 10392–10395 (2019). [DOI] [PubMed] [Google Scholar]
  • 87.Mazzier D, De S, Wicher B, Maurizot V & Huc I Interplay of secondary and tertiary folding in abiotic foldamers. Chem. Sci 10, 6984–6991 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Hayashi T, Hilvert D & Green AP Engineered metalloenzymes with non-canonical coordination environments. Chem. Eur. J 24, 11821–11830 (2018). [DOI] [PubMed] [Google Scholar]
  • 89.Schwizer F et al. Artificial metalloenzymes: Reaction scope and optimization strategies. Chem. Rev 118, 142–231 (2018). [DOI] [PubMed] [Google Scholar]
  • 90.Lee HS & Schultz PG Biosynthesis of a site-specific DNA cleaving protein. J. Am. Chem. Soc 130, 13194–13195 (2008). [DOI] [PubMed] [Google Scholar]
  • 91.Drienovská I, Rioz-Martínez A, Draksharapu A & Roelfes G Novel artificial metalloenzymes by in vivo incorporation of metal-binding unnatural amino acids. Chem. Sci 6, 770–776 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Drienovská I et al. Design of an enantioselective artificial metallo-hydratase enzyme containing an unnatural metal-binding amino acid. Chem. Sci 8, 7228–7235 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Obexer R et al. Emergence of a catalytic tetrad during evolution of a highly active artificial aldolase. Nat. Chem 9, 50 (2016). [DOI] [PubMed] [Google Scholar]
  • 94.Spencer RK, Li H & Nowick JS X-ray crystallographic structures of trimers and higher-order oligomeric assemblies of a peptide derived from Aβ17–36. J. Am. Chem. Soc 136, 5595–5598 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES